Drug Profile
PNU 151807
Latest Information Update: 02 Aug 2002
Price :
$50
*
At a glance
- Originator Pharmacia Corporation
- Class Antineoplastics
- Mechanism of Action Alkylating agents; DNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 06 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
- 14 Oct 1998 New profile
- 14 Oct 1998 Preclinical development for Cancer in Italy (Unknown route)